The Claim
In aged female 3xTg mice, a 7-day treatment with istradefylline at 2 mg/kg/day administered intraperitoneally increases cortical cerebral blood flow by 51%, restoring perfusion to levels observed in healthy aged C57BL/6 mice and young 3xTg mice.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In aged female 3xTg mice, a 7-day injection of istradefylline at 2 mg/kg/day increases cortical cerebral blood flow by 51%, bringing blood flow levels up to those seen in healthy aged mice and young mice with the same genetic model.
See the scientific wording
In aged female 3xTg mice, a 7-day treatment with istradefylline (2 mg/kg/day, intraperitoneal) was associated with a 51% increase in cortical cerebral blood flow, restoring perfusion to levels comparable to healthy aged C57BL/6 mice and young 3xTg mice, suggesting that adenosine A2A receptor blockade may mitigate age- and disease-related hypoperfusion in this Alzheimer’s model.
A drug blocks a brain receptor that becomes overactive with age and Alzheimer's changes. This causes a reduction in a harmful molecule that normally shuts down a key enzyme responsible for making a blood-vessel-relaxing chemical. With the enzyme working again, the blood vessels in the brain widen, increasing blood flow to normal levels.
What the research says
1 studyIn older female mice with Alzheimer’s-like brain changes, a drug called istradefylline helped increase blood flow in the brain, bringing it back up to the level seen in healthy mice. This suggests blocking a specific brain receptor might fix poor blood flow in Alzheimer’s.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.